Oculis Holding AG Logo

Oculis Holding AG

Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.

OCS | IC

Overview

Corporate Details

ISIN(s):
CH1242303498 (+1 more)
LEI:
5067005370C2KK324336
Country:
Switzerland
Address:
Bahnhofstrasse 7, 6300 Zug
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Oculis Holding AG is a global, clinical-stage biopharmaceutical company dedicated to developing innovative therapies to save sight and improve eye care. The company focuses on ophthalmology, addressing diseases with high unmet medical needs through a pipeline of novel treatment candidates. Its key assets include OCS-01, a topical eye drop using its proprietary OPTIREACH® technology for Diabetic Macular Edema (DME); Licaminlimab (OCS-02), an anti-TNFα eye drop for Dry Eye Disease (DED); and Privosegtor (OCS-05), a neuroprotective therapy for Acute Optic Neuritis. Oculis aims to transform treatment paradigms by developing potentially first-in-class, non-invasive therapies for major ocular diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-14 22:05
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 1.2 KB
2025-10-14 10:00
Regulatory News Service
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO …
English 15.5 KB
2025-10-08 22:05
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 949 bytes
2025-10-06 10:07
Regulatory News Service
Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugab…
Icelandic 18.7 KB
2025-10-06 10:07
Regulatory News Service
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neurit…
English 16.8 KB
2025-09-26 22:05
Director's Dealing
Oculis Publishes Notification of Transactions by Person Discharging Managerial …
English 1.0 KB
2025-09-22 10:00
Regulatory News Service
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor …
English 11.4 KB
2025-09-09 22:05
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 952 bytes
2025-09-04 19:00
Regulatory News Service
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
English 6.5 KB
2025-09-03 22:05
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 950 bytes
2025-09-01 10:00
Regulatory News Service
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Op…
English 17.7 KB
2025-08-28 10:00
Regulatory News Service
Oculis to Participate in Upcoming September Investor Conferences
English 6.1 KB
2025-08-25 10:00
Board/Management Information
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-R…
English 13.2 KB
2025-08-21 22:05
Earnings Release
Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri f…
Icelandic 20.6 KB
2025-08-21 22:05
Earnings Release
Oculis Reports Q2 2025 Financial Results and Provides Company Update
English 18.3 KB

Automate Your Workflow. Get a real-time feed of all Oculis Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oculis Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oculis Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.